Solid & liquid biopsy
- 1 block or 25 slides
- 2 blood samples
10 working days
Scroll down to discover
This solution is an integrated approach that combines the analyses of a solid biopsy (by next-generation sequencing (313 genes), IHCs and additional tests) with the analysis of a blood biopsy. The blood profiling focuses either on the circulating tumor DNA (for deciphering tumor heterogeneity) or in DNA from blood cells (for studying specific germline gene alterations related to BRCAness phenotype that are challenging to detect in FFPE samples).
OncoSTRAT&GO establishes a complete genetic profile of the tumor, which can be used to identify sensitivity or resistance to targeted therapies, hormonal therapies, chemotherapies and immunotherapies.
Solid and liquid biopsy
313 genes for the solid biopsy
Variable number of genes for the liquid biopsy depending on the cancer type
10 working days
NGS analysis alone provided information about useful treatments in 27% of the patients. However, the combination of NGS with additional tests of RNA and proteins (OncoDEEP's approach) provided information on available treatments in 92% of the patients (Laes et al., 2018).
92.7% of the oncologists agreed with OncoDNA’s recommendations (Laes et al., 2018).
When our treatment recommendations were followed, 50% of the patients with advanced solid cancer (who had failed at least one line of therapy) showed an overall survival (OS) of more than 6 months; moreover, a 27% had a minimum OS of more than 12 months, while patients at this stage have an average OS of ~3-6 months (Laes et al., 2018).
Our immunogram combines five different biomarkers for predicting clinical benefit of immune checkpoint inhibitors (ICIs): PD-L1 protein expression (FDA-approved marker), TMB, CD8+ T-cell infiltration, MSI (FDA-approved marker) and gene alterations leading to sensibility or resistance to ICIs.
OncoDNA publishes regularly in peer-reviewed international journals.
Here below you will find a selection of key publications supporting our clinical expertise in precision oncology.
Male, 70 years old
We found an EGFR L858R mutation. This is one of the most frequent EGFR mutations in NSCLC (26-40%) and the most common sensitizing mutation to EGFR-TKI therapies, it has been reported to double the phosphorylation effects of EGFR after ligand treatment. NSCLC patients carrying this mutation are responsive to gefitinib and erlotinib therapies. Based on package plus analysis, this patient should be sensitive to gemcitabine based chemotherapy. On the other hand this patient should not be sensitive to taxane, 5-FU based chemotherapies and to ALK/RET/ROS1/NTRK, MET, PI3K and dual PI3K/mTOR inhibitor.
Male, 58 years old
SOLID PART: We found a BRCA2 stop codon. BRCA2 loss of function mutations in the germline have become a hallmark for hereditary breast and ovarian cancers. PARP inhibitors attack tumours defective in the BRCA2 gene by a concept termed ‘synthetic lethality’. If a BRCA2 mutation is present, the breast cancer is less likely to be oestrogen-receptor-positive, which means that the patient may not be a candidate for treatment with hormonal therapy. Several PARP inhibitors are recommended by NCCN guidelines and FDA approved for the treatment of breast cancer HER2-negative, BRCA1/2 positive. Based on package plus analysis, this patient should be sensitive to ER, CDK4/6 inhibitors. On the other hand this patient should not be sensitive to 5-FU based chemotherapy and to HER2, PI3K, dual PI3K/mTOR inhibitors.
LIQUID PART: The hereditary germline cancer panel has been performed on the peripheral blood mononuclear cells. A BRCA2 variant at a frequency of 51% has been found.
Ordering a solution is very simple: Just log in to and select the solution(s) you are interested in. If you do not have a kit for sample collection, we will send you one.
After sample processing and interpretation by our expert team, a comprehensive report will be available for you on our platform OncoSHARE. In a simple and interactive manner, it will help you with the selection of the most appropriate treatments based on the unique signature of your patient's tumour. Moreover, you can share the report with your colleagues.
For information regarding the price of the test(s) in your country, please contact the sales department at . sales@oncodna.com
If your question is not included in the list above or you would like more information about our solutions, please contact us at infos@oncodna.com. Our Patient and Scientific Support teams are available to answer your questions from Monday to Friday. You can also reach us through the chat (icon at the bottom right corner of current window).
OncoDEEP analyses solid biopsies by combining next-generation sequencing (313 genes), IHCs to study protein expression and additional tests. This complete tumor profiling allows to predict patient response to approved or experimental targeted drugs, hormonal therapies, immunotherapies and chemotherapies. The NGS panel is accurately designed according to oncologists’ needs in their current practice. Importantly, it includes an accurate determination of MSI, TMB and LOH. The NGS panel is regularly updated based on new findings reported in the literature in order to provide patients with the most cost-effective solution.
Read more
OncoSELECT is a fast and minimally invasive analysis of circulating tumor DNA from a blood sample. It is the perfect solution to identify therapeutic options for cancer patients not able to have their tumor biopsied or whose biopsy is too old. It can be used as a tool to detect treatment resistance to targeted and hormonal therapies (before first-line to check the heterogeneity of the disease, or during/after treatment to check for acquired resistance mutations), as well as for monitoring cancer progression.
Read more
OncoTRACE by OncoDNA is a test based on the analysis of circulating tumor DNA in blood. It is used to monitor the progression of the tumor (burden of the disease) and to detect lack of response or resistance to treatment as soon as it appears.
This assay is customized for each patient, as it analyses variants previously identified in the tumour of the patient.
In 2013, OncoDNA became the first company to launch a personalised liquid biopsy test.
Read more
